Nagata, Jason M. http://orcid.org/0000-0002-6541-0604
Compte, Emilio J.
Murray, Stuart B.
Schauer, Rebecca
Pak, Erica
Flentje, Annesa
Capriotti, Matthew R.
Lubensky, Micah E.
Lunn, Mitchell R.
Obedin-Maliver, Juno
Funding for this research was provided by:
American Heart Association (CDA34760281)
National Institutes of Health (K23 MH115184)
National Institute of Diabetes and Digestive and Kidney Diseases (K12DK111028)
National Institute on Drug Abuse (K23DA039800)
Patient-Centered Outcomes Research Institute (PPRN‐1501‐26848)
American Academy of Neurology
Article History
Received: 8 July 2020
Accepted: 10 November 2020
First Online: 3 December 2020
Compliance with ethical standards
:
: Dr. Juno Obedin-Maliver has consulted for Sage Therapeutics (5/2017) in a one-day advisory board, Ibis Reproductive Health (a non-for-profit research group 3/2017-5/2018), Hims, Inc. (2019—present) and Folx, Inc (2020—present). Dr. Mitchell R. Lunn has consulted for Hims, Inc. (2019—present) and Folx, Inc (2020—present). None of these roles present a conflict of interest with this work as described here. The other authors have no conflicts of interest to report.
: The University of California, San Francisco Institutional Review Board approved this study on 2 February 2018 (#16-21213). All procedures performed in this study were in accordance with the ethical standards of the university’s Institutional Review Board and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Written informed consent was obtained from all participants.